Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 3/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865546 | 0.93 | BRD4 (0.43) | HRH4BRD4ATAD2F7F3 | |
| SCHEMBL17865525 | 0.90 | F7 (0.41) | HRH4F7F3 | |
| SCHEMBL17865491 | 0.86 | CHEK1 (0.46) | HRH4BRD4ATAD2 | |
| SCHEMBL17865508 | 0.80 | DGAT1 (0.42) | BRD4ATAD2 | |
| SCHEMBL17865497 | 0.79 | HDAC6 (0.48) | HRH4GRIN1 | |
| SCHEMBL3014663 | 0.77 | BRD4 (0.43) | BRD4ATAD2 | |
| SCHEMBL17865542 | 0.75 | HRH4 (0.54) | HRH4 | |
| SCHEMBL17865504 | 0.74 | PIN1 (0.41) | HRH4BRD4ATAD2 | |
| SCHEMBL17865527 | 0.74 | GRIN2D (0.49) | HRH4GRIN1 | |
| SCHEMBL17865657 | 0.73 | HRH4 (0.40) | HRH4BRD4ATAD2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | claimed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | claimed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | claimed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | disclosed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | disclosed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | HRH4 348/4885BRD4 1213/4885ATAD2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.